Author

Qing Li

Shanghai Cancer InstituteORCID 0000-0002-0169-8098Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Qing Li13 papers · Beijing Institute of Technology

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1 Approach:statistical model· 1

Frequent Co-Authors

Chongyi JiangiD· 1 shared Chun-Jie Xu· 1 shared Cun WangiD· 1 shared Dong-Xue Li· 1 shared Fangyuan DongiD· 1 shared Fei Wang· 1 shared Helen He ZhuiD· 1 shared Hong‐Fei YaoiD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Chongyi JiangORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Stromal control of sympathetic rewiring in metastatic lymph nodes

Jun Li, Xiang Zhang, SU Guang-hong, LiPeng Hu, Qing Li, Hui Li, Rui Lu, Ting-Hong Wei, Wen‐Jun Huang, Yao-Qi Zhou, Jia-Xuan Xie, Yang-Yang Wang, Tianshang Bao, Fei Wang, Yan-Kun Li, , Zhigang Zhang

This study shows that tumor-driven remodeling of metastatic lymph nodes involves sympathetic neural rewiring mediated by stromal HGF and mechanical cues.

bioRxiv · Oct 22, 2026 · PreprintCancer Biology

Citalopram exhibits immune-dependent anti-tumor effects by modulating C5aR1+ TAMs

Fangyuan Dong, Shan Zhang, Kaiyuan Song, Luju Jiang, Li-Peng Hu, Qing Li, Xueli Zhang, Jun Li, Mingxuan Feng, Zhiwei Cai, Hong‐Fei Yao, Rong-Kun Li, Hui Li, Jie Chen, Xiaona Hu, , Shu‐Heng Jiang

This study shows citalopram reduces hepatocellular carcinoma by modulating C5aR1+ tumor-associated macrophages and enhancing CD8+ T cell anti-tumor immunity.

eLife · Feb 9, 2026Peer-reviewedCancer Biology